ITGA2B and myeloproliferative disorder: Increased platelet activation, measured by the P-selectin and GPIIb/IIIa expression has also been shown for patients with myeloproliferative disorders and a mixed population of solid cancers, including malignancies from in- and outside the central nervous system [27, 28].